Abaxis Inc. ABAX,End of the trading session trade hit 26.60
Abaxis Inc.
Abaxis, Inc., a medical products company manufacturing point-of-care blood analysis instruments for both the medical and veterinary markets, announced today the appointment of Brenton Hanlon to the position of vice president of North American medical sales and marketing, effective immediately. Mr. Hanlon, a member of the Abaxis Board of Directors since 1996, has resigned his position on the Board to assume this management/operational position within the Company. About Qwest Communications International Inc.
http://StockEinstein.com offers free daily stock alerts on companies ready to run. Scroll to BOTTOM of this page for free stock alerts, or visit our site.
Abaxis, Inc. (Abaxis) develops, manufactures, markets and sells portable blood analysis systems for use in any human or veterinary patient-care setting to provide clinicians with rapid blood constituent measurements. It has two segments: the medical market and the veterinary market. It markets the blood analysis system in the medical market under the name Piccolo xpress. Blood analysis system in the veterinary market is marketed under the name VetScan VS2. Its primary product is a blood analysis system. In April 2009, the Company submitted an assay for C-Reactive Protein (CRP) to the United States Food and Drug Administration (FDA) for 510(k) clearance. In May 2009, it entered into a license agreement with Abbott Point of Care Inc., granting the Company the right to sell and distribute Abbott’s i-STAT 1 handheld instrument (i-STAT 1 analyzer) and associated consumables (for blood gas, electrolyte, basic blood chemistry and immunoassay testing) in the animal healthcare market worldwide.
About Stock Einstein
StockEinstein uses proprietary technologies coupled with years of experience to uncover stocks we feel have the greatest potential for breakout performance. We utilize not only software, but time tested criteria to uncover these potential winners. When these benchmarks are reached or exceeded, our subscribers are immediately notified.
Disclaimer: Full disclaimer at http://StockEinsteain.com/disclaimer.php
IMPORTANT: Never invest in any stock featured in any press release, email or website unless you can afford the loss of your entire investment. Stocks and particularly penny stocks have the possibility for dramatic gains, and also losses. Neither StockEinsteain, nor any of its affiliates are registered investment advisors or broker dealers.
Thank you for your interest in Findit News. A member of the Findit News team will contact you soon to show you how you can take your marketing to the next level with press releases on Findit.
